Alpha-1 Antitrypsin as a Biomarker for Hepatitis B
Author Information
Author(s): Tan Xu-fei, Wu Shan-shan, Li Shu-ping, Chen Zhi, Chen Feng
Primary Institution: State Key Laboratory of Infectious Disease Diagnosis and Treatment, First Affiliated Hospital, College of Medicine, Zhejiang University
Hypothesis
Can alpha-1 antitrypsin (AAT) serve as a biomarker for the progression of hepatitis B?
Conclusion
The study suggests that AAT could be a potential biomarker for diagnosing hepatitis B.
Supporting Evidence
- AAT levels were significantly elevated in serum samples from patients with severe chronic hepatitis.
- Immunoblotting confirmed high expression of AAT in serum from patients with hepatic carcinoma.
- AAT expression was highest in normal tissues and lowest in hepatic carcinoma and severe chronic hepatitis tissues.
Takeaway
This study found that a protein called alpha-1 antitrypsin is higher in people with severe hepatitis B, which might help doctors diagnose the disease better.
Methodology
The study used two-dimensional electrophoresis, peptide mass fingerprinting, and tissue microarray techniques to analyze serum samples.
Limitations
The study did not provide detailed information on the protein origins, which may limit understanding of the disease.
Participant Demographics
31 chronic hepatitis B patients (13 mild and 18 severe), 10 convalescent acute hepatitis B patients, 18 HBV-related Hepatocellular Carcinoma patients, and 12 healthy blood donors.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website